AGC to expand biopharmaceutical production facilities in the US, Denmark

摘要

Asahi Glass (AGC) today announced that it will expand capacity at its AGC Biologics subsidiary in the United States and at its plant in Denmark to reinforce contract development and manufacturing organization (CDMO) business. A 500-liter mammalian cell bioreactor will be added at its Seattle facility in the US, and a new purifcation line will be installed at its Copenhagen, Denmark plant. The total investment is expected to be around ￥2 billion ($18.4 million). Operation is scheduled to begin at the US facility in April 2020, and in October at the plant in Denmark.